[Immunohistochemical study and treatment result of small cell lung carcinoma using combination chemotherapy].
Sixty eight cases of small cell lung carcinoma (SCLC) were treated with Combination chemotherapy regimen of COCE or COMP. Among them, 22 cases received radiotherapy after chemotherapy, and 14 cases were studied with antibodies of NSE (neuron-specific enolase), CCH-A (chromogranin A), CEA (carcino-embryonic antigen) and keratin using an immunohistochemical ABC method. The total remission rate was 58.8% and the MST was 12.8 months. The CR+PR of COCE treated group was 74.3% and the MST was 12.9 months. The CR+PR of COMP treated group was 37.8% and the MST was 10 months. There was statistically significant difference between results of the COCE and COMP-treated groups. The MST of cases who received radiotherapy after chemotherapy was 15 months (COCE 17.3 months, COMP 12 months). It indicated that COCE regimen was more effective than COMP one. The immunohistochemical result showed that 44.4% (6/14) of the cases were positive with NSE and/or CCH-A, and their MAT was longer than that of NSE and/or CCH-A negative cases. It suggests that SCLC with neuroendocrine differentiation has a better prognosis.
1st Affiliated Hospital, Henan Medical University, Zhengzhou.
Q D
QD
Mei
M
M
Yan
X L
XL
Huang
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000737:chemistry / Q000188:drug therapy* / Q000532:radiotherapy; D053379:Chromogranin A; D002864:Chromogranins / Q000032:analysis; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010751:Phosphopyruvate Hydratase / Q000032:analysis; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D053379:Chromogranin A; D002864:Chromogranins; D014750:Vincristine; D005047:Etoposide; D008130:Lomustine; D003520:Cyclophosphamide; D010751:Phosphopyruvate Hydratase; D011241:Prednisone; D008727:Methotrexate